EMA Recommends Five Orphan Drugs
The agency recommended a total of 11 drugs at its July meeting, including five orphan drugs.
The European Medicines Agency announced on July 21, 2017 that its Committee for Medicinal Products for Human Use (CHMP) recommended approval of 11 medicines at its July meeting. The approved medicines include five orphan drugs and included treatments for multiple types of cancer.
The orphan drugs the committee recommended for authorization are:
- Verkazia (ciclosporin), which was under EMA’s accelerated assessment mechanism, for the treatment of severe vernal keratoconjunctivitis in children and adolescents.
- Bavencio (avelumab), for the treatment of Merkel cell carcinoma
- Lutathera (lutetium [177Lu] oxodotreotide), for the treatment of gastro-entero-pancreatic neuroendocrine tumours
- Rydapt (midostaurin), for the treatment of acute myeloid leukaemia, aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, and mast cell leukaemia
- Xermelo (telotristat ethyl), for the treatment of carcinoid syndrome.
CHMP also gave positive opinions to Dupixent (dupilumab), for the treatment of atopic dermatitis; Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), for the treatment of HIV infection; and Tecentriq (atezolizumab), for the treatment of locally advanced or metastatic urothelial carcinoma and of non-small cell lung cancer. Generic drugs Entecavir Accord (entecavir) and Entecavir Mylan (entecavir), both for the treatment of chronic hepatitis B; and Lacosamide Accord (lacosamide), for the treatment of epilepsy, were also given a positive opinion.
Two drugs received a negative opinion: Fanaptum (iloperidone), for the treatment of schizophrenia, and Onzeald (etirinotecan pegol), for the treatment of breast cancer with brain metastases.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
